• 13
  • Image

Microbiome MDx specialist Genetic Analysis signs supply & distribution agreement with Bio-Rad for GA-map™

Press Release: 

Dysbiosis success triggers further investment and development agreement for additional microbiome tests beyond GA-map™ Dysbiosis Test

(Oslo and Hercules, Calif., 12 December 2017) Genetic Analysis (GA) and Bio-Rad Laboratories, Inc., a global provider of life science research and clinical diagnostic products, today announced that they have signed a supply and distribution agreement for Genetic Analysis’s GA-map™clinical test for gut dysbiosis.

The patented GA-map™ technology is used as an aide in the diagnosis and management of irritable bowel syndrome and inflammatory bowel disease.

Dysbiosis is a microbial imbalance or maladaptation on or inside the body and is most commonly reported as a condition in the digestive tract. It has been associated with illnesses, such as inflammatory bowel disease and other chronic diseases.

“We are delighted to enter into this agreement with Bio-Rad,” says Ronny Hermansen, CEO of Genetic Analysis.During the past year, the body of evidence supporting the use of GA-maphas grown considerably. Bio-Rad has the market knowledge and necessary resources to accelerate the uptake of this technology by clinicians worldwide. We look forward to further developing our product portfolio with Bio-Rad’s continuing support.”

“We welcome the opportunity to partner with Genetic Analysis,” says John Hertia, Bio-Rad Executive Vice President, President, Clinical Diagnostics Group.  “With the GA-map technology, we will be able to offer products that can analyze the microbiome associated with gut dysbiosis, which affects the quality of life of many patients around the world and can result in serious health problems.”


For further information, please contact:
Ronny Hermansen

Mobile: +47 924 56 704
E-mail: rh@genet-analysis.com

Bio-Rad Laboratories, Inc.

Tina Cuccia, Corporate Communications
E-mail: tina_cuccia@bio-rad.com


About Genetic Analysis

Genetic Analysis has developed and launched the first gene-based routine test for the mapping and aide in diagnosis of diseases associated with dysbiosis and imbalances in the bacteria in the digestive system. The company markets the GA-map™ technology to three market segments: commercial routine testing, pharma companies and the research market. Genetic Analysis was established in 2008 and is based on research done by Professor Knut Rudi at Norwegian University of Life Sciences, NMBU and Nofima Mat in Ås. www.genetic-analysis.com

About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had net sales exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.

 This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our development and launch of new products and our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “plan”, “believe,” “expect,” “anticipate,” “may,” “will,” “can,” “intend,” “estimate,” “continue,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, product quality and liability issues, our ability to compete effectively, and international legal and regulatory risks. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Report on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Comments are closed.